Home > Drugs A – Z > Enalapril/Hydrochlorothiazide (By mouth)

Enalapril/Hydrochlorothiazide (By mouth)

Treats high blood pressure. This medicine contains an ACE inhibitor and a diuretic (water pill).

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Enalapril and hydrochlorothiazide combination is used to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. Lowering blood pressure… Read more
Brand names include
Drug classes About this
ACE Inhibitor/Thiazide Combination, Antihypertensive, Cardiovascular Agent

What works? Research summarized

Evidence reviews

Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses

This review and network meta-analysis concluded that chlortalidone was better than hydrochlorothiazide for preventing cardiovascular events, in patients with hypertension. There were concerns about the limited search, poor reporting, and indirect analysis, but the results and conclusions are likely to be reliable.

Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials

The authors concluded that hydrochlorothiazide (12.5mg to 25mg daily dose) lowered blood pressure significantly less well than other drug classes used to treat hypertension (measured by 24-hour ambulatory blood pressure monitoring). The reliability of the authors' conclusion is uncertain given potential error and bias in the review process and reliance on only a few high-quality trials.

Drug Class Review: Direct Renin Inhibitors, Angiotensin Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers: Final Report [Internet]

The renin-angiotensin system is a complex biologic system between the heart, brain, blood vessels, and kidneys that leads to the production of biologically active agents, including angiotensin I and II and aldosterone, which act together to impact a variety of bodily functions including blood vessel tone, sodium balance, and glomerular filtration pressure. The multiple and varied effects of these agents allows the renin-angiotensin system to play a wide role in the pathology of hypertension, cardiovascular health, and renal function. Our ability to begin to intervene upon the complex cycle of hormone and other biochemical agent production within the renin-angiotensin system began with the advent of the first orally active ACE-I (angiotensin converting enzyme inhibitor), captopril, in 1981. AIIRAs (angiotensin II receptor blockers) were developed as an alternative to ACE-I, and block the interaction between angiotensin II and the angiotensin receptor. Losartan, the first commercially available AIIRA, was approved for clinical use in 1995. The goal of this report is to compare the effectiveness and harms between aliskiren and placebo and between AIIRAs and ACEIs in the treatment of diagnosed coronary heart disease, hypertension, left ventricular dysfunction, heart failure, nondiabetic chronic kidney disease, or diabetic nephropathy.

See all (27)

PubMed Health Blog...

read all...